Spontaneous late-onset Alzheimer's disease (LOAD) accounts for more than 95% of all human AD. As mice do not normally develop AD and as understanding on molecular processes leading to spontaneous LOAD has been insufficient to successfully model LOAD in mouse, no mouse model for LOAD has been available. Existing mouse AD models are all early-onset AD (EOAD) models that rely on forcible expression of AD-associated protein(s), which may not recapitulate prerequisites for spontaneous LOAD. This limitation in AD modeling may contribute to the high failure rate of AD drugs in clinical trials. In this study, we hypothesized that genomic instability facilitates development of LOAD and tested two genomic instability mice models in the brain pathology at the old age. Shugoshin-1 (Sgo1) haploinsufficient 
oxidative stress, cholesterol metabolism, glycation, and other environmental and lifestyle factors are recognized as aggravating factors (Scheltens et al., 2016) .
Major pathological features of the human AD brain include plaques of amyloid-b made of cleaved APP, tangles of Tau proteins, and congophilic cerebral amyloid angiopathy (Kitazawa, Medeiros, & Laferl, 2012; Onos, Sukoff Rizzo, Howell, & Sasner, 2016; Sasaguri et al., 2016; Scheltens et al., 2016) . With insufficient knowledge on the cause, modeling LOAD in rodents has been an issue. Normally, mice do not develop AD, which has been interpreted as due to their shorter lifespan and sequence differences in APP and Tau. Various transgenic mouse models with modified APP, Tau, and others have been developed for EOAD (Kitazawa et al., 2012; Onos et al., 2016; Sasaguri et al., 2016) . However, LOAD models are limited to apes and are practically nonexistent in rodents. AD drugs developed with EOAD models were explored for use as human LOAD therapy, under an assumption that drugs effective on EOAD would also be effective in treating LOAD. More than 98% of drugs tested in EOAD rodent models were ineffective in human LOAD patients in clinical trials (Cummings, Morstorf, & Zhong, 2014) , raising concerns on current drug targets and on the validity of the EOAD models for human LOAD.
Genomic instability and aneuploidy have been suspected to cause or aggravate AD, as high rates of both are present in the human AD brain (Bajic, Spremo-Potparevic, Zivkovic, Isenovic, & Arendt, 2015) . Further, genomic instability biomarkers have been associated with mild cognitive impairment and AD (Lee, Thomas, & Fenech, 2015) . Aneuploidy may facilitate development of AD-like dementia, as 15% of patients with Down syndrome with chromosome 21 trisomy develop AD-like cognitive dysfunction in their 40s, and the rate increases to 50%-70% by age 60 (Bajic et al., 2015; Potter, 1991) . However, a causal link between CIN, aneuploidy, and AD has not been established.
Genomic instability and aneuploidy have also been suspected to cause cancers (Boveri, 2008) . To investigate the effects of genomic instability and resulting aneuploidy on carcinogenesis, various mouse models have been developed, mainly by targeting mitotic or other cell cycle regulators (Foijer, Draviam, & Sorger, 2008; Rao, Yamada, Yao, & Dai, 2009; Ricke, van Ree, & van Deursen, 2008; Schvartzman, Sotillo, & Benezra, 2010) . Shugoshin-1 (Sgo1) protects cohesin proteins and centrosome integrity (Salic, Waters, & Mitchison, 2004; Sch€ ockel, M€ ockel, Mayer, Boos, & Stemmann, 2011) . Cohesins keep sister chromatids from prematurely separating during mitosis, thus ensuring mitotic fidelity (Hirano, 2015) . The Sgo1 haploinsufficient (∓) mouse is a model of cohesinopathy and chromosome instability (CIN) (Rao et al., 2016; Wang et al., 2008; Yamada et al., 2012 Yamada et al., , 2015 Yamada et al., , 2016 . Sgo1 À/+ model has shown unique transcriptomic signatures at the tissue/organ level and cancer proneness in certain organs including colon, lung, and liver (Rao et al., 2016; Yamada et al., 2012 Yamada et al., , 2015 Yamada et al., , 2016 . In humans, the homolog SgoL1 is frequently mutated or abnormally expressed in cancers, affecting the mitotic process (Iwaizumi et al., 2009; Kahyo et al., 2011; Matsuura et al., 2013; Wang et al., 2015) . Congenital mutations in human SgoL1 lead to chronic atrial and intestinal dysrhythmia syndrome, affecting the heart and gut rhythm (Chetaille et al., 2014) . However, whether the mutations affect AD is unknown. The CAID syndrome is extremely rare disease. Chetaille et al. (2014) originally reported only 17 patients. The disease-associated SgoL1 missense mutation was found in <1% in public database. A likely reason for the rarity of CAID syndrome is that congenital mutation in human SgoL1 may not be compatible with early development. In mouse, Sgo1 is highly expressed in heart, gut, and CNS during early development (Song et al., 2017a (Song et al., , 2017b , and Sgo1 À/À (knockout) is embryonic lethal (Yamada et al., 2012) ; strongly suggesting essential function of Sgo1 and SgoL1 during early development. Also, this study is the first ever study linking Sgo1 and AD. As such, no study focusing on correlation between the CAID syndrome and AD has been performed thus far.
BubR1 is a mitotic spindle checkpoint component. BubR1
mice showed mitotic slippage in the cells and were colon cancerprone (Dai et al., 2004; Rao et al., 2005) , and BubR1 H/H hypomorphic mice were identified as a model for premature aging (Baker et al., 2004) . Neuronal cell division and axon growth were inhibited by siRNA-mediated BubR1 knockdown in the mouse brain (Yang et al., 2017) . The above findings in BubR1 transgenic models led to a hypothesis that mitotic errors and CIN facilitate AD-like neurodegeneration.
With the current gap in LOAD study models, we hypothesized that LOAD development is facilitated by genomic instability with Figure S1 ).
APBB1 encodes a protein involved in DNA damage repair, interacts with APP, and is thought to promote AD. The pilot result at a younger age led us to suspect that the brains of Sgo1 À/+ mice would show signs of neurodegenerative disease similar to AD.
| Sgo1
À/+ brains accumulated amyloid-b by
months of age
An aging-and-carcinogenesis study cohort provided Sgo1 À/+ brains at older ages (24-25 months) corresponding to human old age over 65. We also collected brains from BubR1 
| p-H3 expression in Sgo1 was observed both in the cortex and in the hippocampus, while p-H3 expression is limited to the hippocampus in wild type
Dentate Gyrus (DG) and subgranular zone in hippocampus are known to be sites for adult neurogenesis (Bordiuk, Smith, Morin, & Sem€ enov, 2014) . Hippocampus is also known to be the site functionally affected by LOAD, leading to the primary LOAD symptom of memory defect.
We tested whether amyloid-b-and-p-H3-positive cells in Sgo1 ten genes were identified (Table 1) . ARC, PMCH, Gm20388, and
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| 5 of 11 AA465934 were overexpressed, while Shisa8, Ebf3, DAO, Slc6a5, PPP1r17, and PCP2 were underexpressed (Figure 4) . Among the ten genes, seven had known connections to AD and/or neuronal function. Gm20388 product carries partial homology to Low-Density Lipoprotein Receptor Class A domain (LDLa) and may be involved in cholesterol metabolism, an AD-associated pathway. (Endo, 2012) . Protein phosphatase 1 can dephosphorylate p-TAU (Liu, Grundke-Iqbal, Iqbal, & Gong, 2005 human AD brain showed a cytoplasmic, diffused pattern of p-H3 (Ogawa et al., 2003) , which was recapitulated in the Sgo1 À/+ mouse brain (Figures 2d and 3a,b) . These reports strongly suggest that human LOAD development can be aided by prolonged mitosis, which the Sgo1 À/+ model recapitulates. Indeed, in human LOAD, models incorporating the critical role of mitotic cells have been proposed, such as a "simple linear model" that states that human AD pathology develops from mitotic cycle-reentering neurons that later die (Herrup, 2010) , and the "two-hit model" of human LOAD (Zhu, Lee, Perry, & Smith, 2007; Zhu, Raina, Perry, & Smith, 2004 ) that purports that LOAD development occurs with (a) oxidative stress and (b) mitotic reentry.
| Overexpressed genes in Sgo1

| Underexpressed genes in Sgo1
Although the direct trigger for mitotic cycle reentry in Sgo1 À/+ model mice remains unclear, studies on roles of cell cycle regulators, such as Cdk5 (Zhang et al., 2008) , and on effects of genes identified through RNA-seq in this study on the cell cycle, are warranted.
The Sgo1 À/+ haploinsufficient mouse is a model that displays two direct effects of a reduction in Sgo1, both of which lead to prolonged mitosis via the spindle checkpoint: (a) cohesinopathy in mitotic chromosome; and (b) defects in centrosome integrity (Yamada et al., 2012) . Whether the AD pathology is caused by cohesinopathy, centrosome defect, or the common consequence that is prolonged mitosis must be distinguished. Cohesinopathy in humans leads to diseases with cancer proneness, developmental malformation, and/or intellectual disability and behavioral issues, such as Cornelia de
Lange syndrome or mutations in STAG1 or STAG2 (Kline et al., 2017; Kumar et al., 2015) . The symptoms suggest that maintenance of chromosome cohesion may play a role more critical than previously anticipated in brain functions.
Mutations in centrosomal genes are often connected to developmental malformations of the brain, such as autosomal recessive primary microcephaly, microcephalic osteodysplastic primordial dwarfism type II, and Seckel syndrome, in humans (Nigg, Caj anek, & Arquint, 2014) . These rare human diseases have not been studied in the context of AD, in part because they are rare yet patients do not survive long, and because mental retardation symptom is difficult to distinguish from cognitive dysfunction of AD. However, the use of corresponding mouse models should provide guidance. At this moment, we do not think Sgo1 is the only target gene to create spontaneous LOAD mouse model. We speculate that functional equivalent of Sgo1 mutation can also create LOAD model. Indeed, functional equivalent of Sgo1 mutation, such as accumulation of aneuploid cells (Bajic et al., 2015; Potter, 1991) or increase in cells reentering mitotic cycle, does occur in human LOAD (Herrup, 2010; Zhu et al., 2004 Zhu et al., , 2007 .
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Our results also suggest that prolonged mitosis and/or mitotic spindle checkpoint may have potential as a therapeutic target for AD. Agreeing with this prediction, Flavopiridol, a CDK inhibitor, reversed memory impairment in amyloid-b-injected AD mouse model, suggesting the detrimental role of prolonged mitosis in AD (Leggio et al., 2016) .
Here, we present evidence that the Sgo1 À/+ haploinsufficient mouse model displays AD-like brain pathology at an age equivalent to human old age. The model will allow us to test genetic interactions between known AD-associated genes (e.g., APOE, ARC) through simple breeding, as well as the influence from environmen- (Rao et al., 2016; Yamada et al., 2012 Yamada et al., , 2015 Yamada et al., , 2016 , and BubR1 À/+ (Dai et al., 2004; Rao et al., 2005) mice were bred and maintained in a pathogen-free rodent barrier facility without treatment for 24-25 months (an observational study). Surviving animals were euthanized and organs were collected following our standard operating procedures (Yamada et al., 2012) . Animal numbers were as follows: WT, 
| Immunoblots
Frozen brain samples (mouse cerebrum including cortex and hippocampus, excluding olfactory bulb, cerebellum, medulla) were extracted in extraction buffer and subjected to immunoblots following our standard protocol (Rao et al., 2016; Yamada et al., 2012) .
Blots were quantified using IMAGEJ 1.43 software (NIH). b-actin blots were used for loading control and normalization.
| Immunofluorescence
Formalin-fixed brain hemispheres were embedded in paraffin and sectioned onto slides. After deparaffinization, antigen retrieval, sodium borohydride treatment, CuSO 4 treatment, and blocking, the slides were treated with primary antibodies for 16 hr, then with secondary fluorescent antibodies for 1 hr, followed by brief DAPI staining and sealing with antifade. Sodium borohydride and CuSO 4 were used to minimize autofluorescence by Shiff-base and by Lipofuscin, respectively (Schnell, Staines, & Wessendorf, 1999; Spitzer, Sammons, & Price, 2011) . 
| Quantification of Immunofluorescence
In the experiment in Figure 3 and Supporting Information Figure 
| RNA-seq
Comparative RNA sequencing was performed as in (Rao et al., 2016; Yamada et al., 2016 
| Data and materials availability
The RNA-seq dataset was deposited to the NIH-GEO database (accession number GSE115185) and will be available there on June Research core facility. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the Laboratory for Molecular Biology and Cytometry Research at OUHSC for the use of the Core Facility, which provided RNA-seq-bioinformatics service.
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